More on ESALF
Data
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $30.61 |
|
|||
| Open | $30.61 | ||||
| 52 Wk High | $66.25 | ||||
| 52 Wk Low | $53.50 | ||||
| Day High | $30.61 | ||||
| Day Low | $30.61 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 300 | ||||
- Eisai and Osaka Prefecture Enter into Collaboration to Promote Awareness of Dementia and Mild Cognitive Impairment (MCI)
- LEQEMBI IQLIK(R) (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease
- Pfizer and Eisai Commence Co-promotion of "NURTEC(R)" for the Acute Treatment and Prophylaxis (Preventive Treatment) of Migraine
- EMA accepts Eisai's lemborexant application for insomnia treatment
- Marketing Authorization Application for In-house Developed Insomnia Drug Lemborexant Accepted for Evaluation by European Medicines Agency (EMA)
- LEQEMBI(R) Real-World LEADER Study Presented at AAIC(R) 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months
- FDA approves Leqembi Iqlik subcutaneous injection for Alzheimer's
- FDA Approves LEQEMBI IQLIK(R) (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
- Eisai Presents Latest Findings Showed Etalanetug Reduced Alzheimer's Disease Tau Tangle-Specific Plasma Biomarker MTBR-tau243 at Alzheimer's Association International Conference(R) (AAIC(R))
- LEQEMBI(R) Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International
Entities mentioned with ESALF
- FDA | View Related Stories »
- Twitter | View Related Stories »
- PDUFA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- S1 | View Related Stories »
- AdCom | View Related Stories »
- Morningstar, Inc. | View Related Stories »
- Show More...
